RECURRENT OVARIAN CANCER
Clinical trials for RECURRENT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cholesterol drug shows promise in ovarian cancer trial
Disease control CompletedThis pilot study tested whether adding simvastatin, a cholesterol-lowering drug, to standard chemotherapy could slow cancer growth in 18 women with recurrent, platinum-sensitive ovarian cancer. Participants received simvastatin alongside carboplatin and liposomal doxorubicin. The…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: EARLY_PHASE1 • Sponsor: Marc Goodman • Aim: Disease control
Last updated May 26, 2026 08:49 UTC
-
New hope for ovarian cancer? drug combo shows promise in trial
Disease control CompletedThis study tested a new drug combination (relacorilant plus nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back after platinum-based treatment. The goal was to see if the combo could delay cancer growth better than nab-paclitaxel alone. …
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:40 UTC
-
New drug combo shows promise for tough ovarian cancer
Disease control CompletedThis early-stage study tested whether adding a new drug called LDE225 to a standard chemotherapy (paclitaxel) is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen women took part to find the best dose and monitor side effects. The go…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated May 22, 2026 14:03 UTC